Melissa Medina1, Shannon R Foiles2, Matilde Francois1, Carl V Asche3, Jinma Ren3, Dale K Mueller2, Richard C Anderson4. 1. University of Illinois College of Medicine, Peoria, IL, USA. 2. Department of Thoracic Surgery, OSF Saint Francis Medical Center, Peoria, IL, USA. 3. Center for Outcomes Research, University of Illinois Department of Medicine, Peoria, IL, USA. 4. Department of Thoracic Surgery, OSF Saint Francis Medical Center, Peoria, IL, USA. Electronic address: randerson@peoriasurgical.com.
Abstract
BACKGROUND: Thoracic Epidural has long been the most recommended treatment for postoperative pain management in general thoracic surgery. This study compares liposomal bupivacaine (LB) as an alternative method for pain control and compares it to the standard. METHODS: LB was compared to thoracic epidural bupivacaine hydrochloride (TE BH) in 387 patients who underwent video-assisted thoracoscopic pulmonary resection (VATS-R) at our institution. Patients received either continuous TE BH or intraoperative LB at a predetermined dose. A total of 237 patients received TE BH from April 2010 to March 2014 and 143 patients received LB from April 2014 to March 2016. After propensity matching, 95 patients in each group had similar demographics and clinical characteristics including gender, age, race, American Society of Anesthesia (ASA) classification, Zubrod scores, and FEV1 and DLCO percent predicted measurements. Outcome measures included hospital costs, length of stay (LOS), adverse events, postoperative opioid medication use, and pain scores. RESULTS: Compared to the TE BH group, the LB group had significantly lower pain scores (average visual analogue scale the day of surgery: 3.9 versus 4.5, p < 0.05), decreased postoperative opioid medication (morphine equivalent dose during the first 3 days: 344.5 versus 269.5, p < 0.05), and lower total and direct hospital costs ($2906 and $1865 respectively, p < 0.05). Although a shorter LOS in the LB group was not statistically significant (4.3 versus 5.1 days, p = 0.156), more patients in the LB group were discharged directly home than the control group (44.2% versus 28.4%, p < 0.05). There was no difference noted in overall adverse events including 30-day readmissions between the two groups. CONCLUSION: LB is a viable alternative for pain management in patients undergoing VATS-R. With recent scrutiny on healthcare costs and the opioid epidemic, these results are encouraging and should be further investigated. Published by Elsevier Inc.
BACKGROUND: Thoracic Epidural has long been the most recommended treatment for postoperative pain management in general thoracic surgery. This study compares liposomal bupivacaine (LB) as an alternative method for pain control and compares it to the standard. METHODS:LB was compared to thoracic epidural bupivacaine hydrochloride (TE BH) in 387 patients who underwent video-assisted thoracoscopic pulmonary resection (VATS-R) at our institution. Patients received either continuous TE BH or intraoperative LB at a predetermined dose. A total of 237 patients received TE BH from April 2010 to March 2014 and 143 patients received LB from April 2014 to March 2016. After propensity matching, 95 patients in each group had similar demographics and clinical characteristics including gender, age, race, American Society of Anesthesia (ASA) classification, Zubrod scores, and FEV1 and DLCO percent predicted measurements. Outcome measures included hospital costs, length of stay (LOS), adverse events, postoperative opioid medication use, and pain scores. RESULTS: Compared to the TE BH group, the LB group had significantly lower pain scores (average visual analogue scale the day of surgery: 3.9 versus 4.5, p < 0.05), decreased postoperative opioid medication (morphine equivalent dose during the first 3 days: 344.5 versus 269.5, p < 0.05), and lower total and direct hospital costs ($2906 and $1865 respectively, p < 0.05). Although a shorter LOS in the LB group was not statistically significant (4.3 versus 5.1 days, p = 0.156), more patients in the LB group were discharged directly home than the control group (44.2% versus 28.4%, p < 0.05). There was no difference noted in overall adverse events including 30-day readmissions between the two groups. CONCLUSION:LB is a viable alternative for pain management in patients undergoing VATS-R. With recent scrutiny on healthcare costs and the opioid epidemic, these results are encouraging and should be further investigated. Published by Elsevier Inc.
Authors: P L Narendra; Harihar V Hegde; K Chandrashekharappa; Vrinda V Tore; Preetish Endigeri; Mahesha Boodadi; Dayanand G Talikoti; Maroof Ahmad Khan Journal: Anesth Essays Res Date: 2019 Jul-Sep
Authors: Kian Banks; Sora Ely; Diana S Hsu; Dana A Dominguez; Rebecca C Gologorsky; Julia Wei; Clara Maxim; Simon K Ashiku; Ashish R Patel; Jeffrey B Velotta Journal: J Thorac Dis Date: 2022-01 Impact factor: 2.895
Authors: L N Spaans; M G W Dijkgraaf; P Meijer; J Mourisse; R A Bouwman; A F T M Verhagen; F J C van den Broek Journal: BMC Surg Date: 2022-09-04 Impact factor: 2.030